Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0562 in advanced solid tumors
NCT02318394Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tavolimab in solid tumor (advanced stage), sponsored by MedImmune. Primary endpoint: Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs). Started Mar 2015; status: completed.
02
Drugs
tavolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02318394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318394.